Safety and Efficacy of Dutogliptin in Patients With Type... | NCT00970424 | Trialant

Safety and Efficacy of Dutogliptin in Patients With Type... | NCT00970424 | Trialant

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
1	Placebo Comparator	placebo, oral tablet administered once daily on background of pioglitazone	Drug: Placebo
2	Experimental	dutogliptin, oral tablet administered once daily on background of pioglitazone	Drug: Dutogliptin

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Hemoglobin A1c Level (HbA1c)		HbA1c is drawn at Visit 1 (Week -16 to -4), Visit 3 (Week -2), Visit 4 (Week 0), Visit 5 (Week 4), Visit 6 (Week 10), Visit 7 (Week 18) and Week 8 (Week 26)

Secondary Outcomes

Measure	Description	Time Frame
Fasting Plasma Glucose Level (FPG)		FPG is drawn at Visit 1 (Week -16 to -4), Visit 2 (Week -4), Visit 3 (Week -2), Visit 4 (Week 0), Visit 5 (Week 4), Visit 6 (Week 10), Visit 7 (Week 18) and Visit 8 (Week 26).

Contacts/Locations Module